The Connective Tissue Growth Factor pipeline drugs market research report outlays comprehensive information on the Connective Tissue Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Connective Tissue Growth Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Musculoskeletal Disorders, Oncology, and Respiratory which include the indications Liver Fibrosis, Liver Cirrhosis, Fibrosis, Breast Cancer, Melanoma, and Idiopathic Pulmonary Fibrosis. It also reviews key players involved in Connective Tissue Growth Factor targeted therapeutics development with respective active and dormant or discontinued products.
The Connective Tissue Growth Factor pipeline targets constitutes close to 13 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 8, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Connective Tissue Growth Factor overview
Connective tissue growth factor (CTGF), also known as CCN2 is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins. CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis (TGF-beta-dependent). This includes fibrosis of major organs, fibroproliferative diseases, and scarring. CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing.
For a complete picture of Connective Tissue Growth Factor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
